SynthesisFrontiers in oncology2026
Effect of sugammadex on postoperative pulmonary complications in patients undergoing video-assisted thoracoscopic lung surgery.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative pulmonary complications (PPCs) remain common after video-assisted thoracoscopic (VATS) lung surgery. Whether sugammadex reduces the incidence of PPCs compared with traditional antagonists remains uncertain. This meta-analysis aimed to evaluate the impact of sugammadex on PPCs in patients undergoing VATS pulmonary resection. Methods: This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020). PubMed, Web of Science, Cochrane Library, and CNKI were searched from inception to December 13, 2024. Randomized controlled trials (RCTs) and cohort studies comparing sugammadex with other antagonists (e.g., neostigmine or pyridostigmine) in patients undergoing VATS pulmonary resection were included. The primary outcome was overall PPCs. Risk of bias was assessed using the Cochrane risk-of-bias tool for RCTs and the Newcastle-Ottawa Scale (NOS) for cohort studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using fixed- or random-effects models according to heterogeneity. Results: Nine studies involving 2,240 patients were included, of which eight reported data on overall PPCs and were included in the primary meta-analysis. Sugammadex significantly reduced the incidence of overall PPCs compared with control agents (OR = 0.68, 95% CI: 0.58-0.80, P < 0.001; I² = 23.9%). Subgroup analyses stratified by study design, type of resection, and disease showed consistent results. Among specific PPCs, sugammadex was associated with a lower risk of atelectasis (OR = 0.61, 95% CI: 0.47-0.80, P < 0.001), whereas no significant differences were observed for pneumonia or other complications. Conclusions: Sugammadex may effectively reduce the risk of PPCs, particularly atelectasis, in patients undergoing VATS pulmonary resection. Further large-scale, high-quality studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.